Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Wanxing Duan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2851-2513; OpenAlex author ID A5012438384. Sources: OpenAlex.

Their work

Papers
51 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2012: 2 papers · 2013: 4 papers · 2014: 6 papers · 2015: 7 papers · 2016: 6 papers · 2017: 4 papers · 2018: 7 papers · 2019: 5 papers · 2020: 3 papers · 2021: 2 papers · 2022: 4 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 50 of 51

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  2. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  3. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Co-author DOI 10.1038/s41419-022-04799-5↗
  4. Resveratrol Exerts Antitumor Effects on Pancreatic Cancer by Inhibiting Notch Signaling Induced by Chronic Stress Last author DOI 10.21203/rs.3.rs-2305575/v1↗
  5. Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. Co-author DOI 10.3389/fonc.2022.923982↗
  6. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Co-author DOI 10.1016/j.isci.2021.103400↗
  7. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  8. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  9. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  10. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  11. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  12. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  13. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  14. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  15. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  16. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  17. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1016/j.lfs.2018.07.046↗
  18. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Last author DOI 10.1159/000494547↗
  19. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  20. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Co-author DOI 10.3892/or.2018.6281↗
  21. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  22. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Last author DOI 10.3892/or.2018.6696↗
  23. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  24. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  25. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  26. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  27. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  28. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  29. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  30. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  31. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗
  32. Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Co-author DOI 10.3892/or.2016.4709↗
  33. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Co-author DOI 10.1080/15384047.2015.1040952↗
  34. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  35. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  36. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  37. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. First author DOI 10.18632/oncotarget.3663↗
  38. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗
  39. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.5045↗
  40. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  41. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Co-author DOI 10.1016/j.febslet.2014.01.007↗
  42. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Co-author DOI 10.1155/2014/546353↗
  43. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  44. Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer. Co-author DOI 10.2174/1568009614666140331231658↗
  45. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  46. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0609↗
  47. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Co-author DOI 10.1186/1476-4598-12-66↗
  48. Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells. Co-author DOI 10.2174/09298673113209990249↗
  49. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Co-author DOI 10.2174/09298673113209990251↗
  50. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathw… Co-author DOI 10.1016/j.canlet.2012.02.035↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 49 shared papers, 2012–2025 · strength 3.44
  2. Jiguang Ma · 33 shared papers, 2013–2025 · strength 2.20
  3. Weikun Qian · 20 shared papers, 2017–2025 · strength 2.08
  4. Qinhong Xu · 30 shared papers, 2012–2020 · strength 1.48
  5. Xuqi Li · 28 shared papers, 2012–2020 · strength 1.47
  6. Jianjun Lei · 26 shared papers, 2012–2021 · strength 1.38
  7. Zheng Wang · 21 shared papers, 2012–2022 · strength 1.32
  8. Cancan Zhou · 16 shared papers, 2016–2022 · strength 1.27
  9. Erxi Wu · 24 shared papers, 2012–2022 · strength 1.27
  10. Zhengdong Jiang · 18 shared papers, 2015–2019 · strength 1.10
  11. Liang Cheng · 13 shared papers, 2017–2020 · strength 0.99
  12. Zheng Wu · 14 shared papers, 2013–2022 · strength 0.93
  13. Liang Han · 10 shared papers, 2013–2025 · strength 0.83
  14. Ke Chen · 11 shared papers, 2016–2021 · strength 0.79
  15. Liankang Sun · 11 shared papers, 2016–2020 · strength 0.78
  16. Ying Xiao · 7 shared papers, 2018–2022 · strength 0.72
  17. Liang Han · 11 shared papers, 2013–2022 · strength 0.68
  18. Junyu Cao · 9 shared papers, 2017–2019 · strength 0.66
  19. Tao Qin · 5 shared papers, 2018–2025 · strength 0.65
  20. Wei Li · 10 shared papers, 2013–2022 · strength 0.59
  21. Jie Li · 7 shared papers, 2017–2021 · strength 0.59
  22. Zheng Wang · 4 shared papers, 2015–2025 · strength 0.57
  23. Bin Yan · 7 shared papers, 2017–2019 · strength 0.50
  24. Tao Qin · 5 shared papers, 2018–2021 · strength 0.47
  25. Xin Chen · 6 shared papers, 2015–2018 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.